May 29 2010
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that its initial public offering of 4,600,000 shares of its common stock has been priced at $6.00 per share. The shares are expected to begin trading today on the NASDAQ Global Market under the ticker symbol "GNMK." In addition, GenMark has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares to cover over-allotments, if any.
Piper Jaffray & Co. is acting as sole book-running manager of the offering. The co-managers are William Blair & Company, L.L.C. and ThinkEquity LLC. A registration statement relating to the shares of GenMark's common stock offered in the initial public offering has been declared effective by the Securities and Exchange Commission.